De Novo
DEN140004: QUIDEL MOLECULAR DIRECT HSV 1 +2/VZV ASSAY
FDA De Novo · diagnostic hybrids, inc. · decided May 13, 2014
Key facts
| De Novo number | DEN140004 |
|---|---|
| Device name | QUIDEL MOLECULAR DIRECT HSV 1 +2/VZV ASSAY |
| Applicant | diagnostic hybrids, inc. |
| Product code | PGI |
| Date received | Feb 21, 2014 |
| Decision date | May 13, 2014 |
| Decision | granted (DENG) |
| FDA classification | Class II |
| Review panel | Microbiology |
| FEI number | 1000122536 |
At a glance
- None Later 510(k)s citing this De Novo
- None UDI device identifiers (GUDID)
- None MAUDE adverse event reports
- None Recall events
- No Decision summary on file
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About De Novo classification requests
The De Novo pathway classifies novel low- to moderate-risk devices that have no legally marketed predicate; each granted request creates a new classification regulation and product code.
Source: U.S. Food and Drug Administration (FDA), De Novo database · Source date: